2026-07-22T03:37:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/199962024-11-28T16:36:31Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16958col_20.500.12105_16967

00925njm 22002777a 4500 dc Garcia-Delgado, Regina author de Miguel, Dunia author Bailen, Alicia author Ramon Gonzalez, Jose author Bargay Lleonart, Joan author Falantes, Jose F. author Andreu, Rafael author Fernando, Ramosh author Tormo, Mar author Brunet, Salut author Figueredo, M. A. author Casano, Javier author Medina, Angeles author Badiella, Llorenc author Fernandez Jurado, Antonio author Sanz, Guillermo author Asociacion Andaluza de Hematologia author 2014-07 We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. Garcia-Delgado R, De Miguel D, Bailen A, Ramon Gonzalez J, Bargay Lleonart J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744-50. Epub 2014 Mar 19. 10.1016/j.leukres.2014.03.004 0145-2126 Leukemia Research http://hdl.handle.net/20.500.13003/17327 24795069 L53121904 2-s2.0-84902116204 http://hdl.handle.net/20.500.12105/19996 339339400005 Acute myeloid leukemia Azacitidine Dosing schedules Myelodysplastic syndromes Overall survival Safety Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia